ME02300B - Anti cd37 antitijela - Google Patents
Anti cd37 antitijelaInfo
- Publication number
- ME02300B ME02300B MEP-2015-191A MEP19115A ME02300B ME 02300 B ME02300 B ME 02300B ME P19115 A MEP19115 A ME P19115A ME 02300 B ME02300 B ME 02300B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (24)
1. Himerni molekul antitjela koji se vezuje za humani CD37 i koji je definisan sa i.varijabilnim teškim lancem koji sadrži amino kiselinsku sekvencu prikazanu u SEQ ID NO: 2; ii.varijabilnim lakim lancem koji sadrži amino kiselinsku sekvencu prikazanu u SEQ ID NO: 4, iii.konstantnim teškim i lakim lancima koji su ljudskog porjekla.
2.Molekul antitjela prema zahtjevu 1, pri čemu i) konstantni teški lanac je IgGl lanac, i ii) konstantni laki lanac je kapa lanac.
3.Molekul antitjela prema zahtjevu 1 ili 2, pri čemu navedeni molekul antitjela ima jedan ili više mutacija u Fc domenu koji modulira jedan ili više efektorskih funkcija, poželjno navedena modulacija efektorske funkcije, je povećana u antitjelno zavisnoj ćelijsko posredovanoj citotoksičnosti.
4.Molekul antitjela prema zahtjevu 3, pri čemu navedena jedna ili više mutacija u Fc domenu je kombinacija supstitucija na položajima 239 i 332, ili 236 i 332, ili 236, 239 i 332, numerisane prema Kabat EU indeksu numerisanja, poželjno navedene supstitucije su I332E i S239D ili I332E i G236A, ili S239D, I332E i G236A.
5.Molekul antitjela prema bilo kom od zahtjeva 1 do 4 koji ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 28 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 30.
6.Antitjelni molekul prema bilo kom od zahtjeva 1 do 4 koji ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 32 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 34.
7.Antitjelni molekul prema bilo kom od zahtjeva 1 do 4 koji ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO:24 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO:26.
8.Antitjelo koje se vezuje za humani CD37 i ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 28 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 30.
9.Antitjelo koje se vezuje za humani CD37 i ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 32 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 34.
10. Antitjelo koje se vezuje za humani CD37 i ima teški lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 24 i laki lanac koji sadrži amino kiselinsku sekvencu SEQ ID NO: 26.
11. DNK molekul koji sadrži region koji kodira varijabilni teški lanac antitjela prema zahtjevu 1 do 10, region koji kodira varijabilni laki lanac antitela prema zahtjevima 1 do 10.
12. DNK molekul prema zahtjevu 11, pri čemu navedeni varijabilni teški lanac koji kodira region je spojen za region koji kodira konstantni teški lanac ljudskog porekla, poželjno navedeni humani konstantni teški lanac je IgGl i poželjni navedeni humani konstantni teški lanac ima jedan ili više supstitucija u Fc regionu.
13. DNK molekul prema zahtjevu 12, pri čemu navedeni IgGl je kodiran sa sekvencom prikazanom u SEQ ID NO: 27 ili SEQ ID NO: 31 ili SEQ ID NO: 23.
14. DNK molekul prema zahtjevu 11, pri čemu navedeni varijabilni laki lanac koji kodira region je spojen za regijon koji kodira konstantni laki lanac ljudskog porjekla, poželjno navedeni konstantni laki lanac je kapa lanac.
15. DNK molekul prema zahtjevu 14, pri čemu navedeni kapa laki lanac je kodiran sa sekvencom prikazanom u SEQ ID NO: 29 ili SEQ ID NO: 33 ili SEQ ID NO: 25.
16.Ekspresioni vektor koji sadrži DNK molekul prema bilo kom od zahtjeva 11 do 15, poželjno vektor sadrži DNK molekul prema zahtjevu 13 i/ili DNK molekul prema zahtjevu 15.
17. Ćelija domaćina koja nosi jedan ili više vektora prema zahtjevu 16.
18. Postupak za proizvodnju antitjela prema bilo kom od zahtjeva 1 do 10, koji sadrži transfektovanje ćelije domaćina sisara sa jednim ili više vektora prema zahtjevu 16, kultivisanje ćelije domaćina i oporavak i prečišćavanje molekula antitela.
19. Farmaceutska komponzicija koja sadrži, kao aktivni sastojak, jedan ili više molekula anti-CD37 antitjela prema bilo kom od zahtjeva 1 do 10, i farmaceutski prihvatljivi nosač.
20. Farmaceutska kompozicija prema zahtjevu 19, dalje sadrži jedan ili više dodatnih terapeutskih agenasa.
21.Farmaceutska kompozicija prema zahtjevu 20, pri čemu navedeni jedan ili više terapeutskih agenasa su agensi koji ciljaju B ćeliju antigena CD20.
22. Farmaceutska kompozicija prema zahtjevu 19 do 21 za korišćenje u smanjenju B ćelijama koje iskazuju CD37 na njihovoj površini.
23.Farmaceutska kompozicija prema zahtjevu 19 do 21 za korišćenje u liječenju B ćelijske malignosti ili autoimunih ili inflamatornih oboljenja koja obuhvataju B ćelije u njihovoj patologiji, poželjno navedena malignost B ćelije je odabrana iz B ćelije ne-Hodgkinsonovog limfoma, B ćelije hronične limfocitne leukemije i multipla mijeloma.
24. Postupak smanjivanja CD37 koje iskazuju B ćelije iz populacije ćelija, koje sadrže primenu na navedene populacije ćelija molekula antitjela prema bilo kom od zahtjeva 1 do 10 ili farmaceutske komponzicije koja sadrži takav molekul antitjela, pri čemu je navedeni postupak izveden in vitro.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114128 | 2007-08-09 | ||
| EP08787055.6A EP2178915B1 (en) | 2007-08-09 | 2008-08-08 | Anti cd37 antibodies |
| PCT/EP2008/060464 WO2009019312A2 (en) | 2007-08-09 | 2008-08-08 | Anti cd37 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02300B true ME02300B (me) | 2016-06-20 |
Family
ID=38925567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-191A ME02300B (me) | 2007-08-09 | 2008-08-08 | Anti cd37 antitijela |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US20100189722A1 (me) |
| EP (3) | EP2178915B1 (me) |
| JP (3) | JP5325216B2 (me) |
| KR (1) | KR101593403B1 (me) |
| CN (4) | CN105273086A (me) |
| AR (2) | AR071242A1 (me) |
| AU (1) | AU2008285590B2 (me) |
| BR (2) | BRPI0823331A2 (me) |
| CA (1) | CA2693464C (me) |
| CL (3) | CL2008002349A1 (me) |
| CO (1) | CO6251371A2 (me) |
| CY (1) | CY1117101T1 (me) |
| DK (1) | DK2178915T3 (me) |
| EA (2) | EA201200994A1 (me) |
| EC (2) | ECSP109946A (me) |
| ES (1) | ES2555202T3 (me) |
| HK (1) | HK1220708A1 (me) |
| HR (1) | HRP20160009T1 (me) |
| HU (1) | HUE026221T2 (me) |
| IL (1) | IL202645A (me) |
| MA (1) | MA32665B1 (me) |
| ME (1) | ME02300B (me) |
| MY (1) | MY157555A (me) |
| NZ (2) | NZ600022A (me) |
| PE (3) | PE20140196A1 (me) |
| PH (1) | PH12014501812B1 (me) |
| PL (1) | PL2178915T3 (me) |
| PT (1) | PT2178915E (me) |
| RS (1) | RS54359B1 (me) |
| SG (1) | SG190657A1 (me) |
| SI (1) | SI2178915T1 (me) |
| TN (1) | TN2010000068A1 (me) |
| TW (2) | TW201512220A (me) |
| UA (2) | UA103005C2 (me) |
| UY (1) | UY31275A1 (me) |
| WO (1) | WO2009019312A2 (me) |
| ZA (1) | ZA200908758B (me) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| WO2009042618A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| JP5944831B2 (ja) * | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ | 抗ｆｌｔ３抗体及びその使用方法 |
| NO331080B1 (no) | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| SMT201900549T1 (it) * | 2010-03-12 | 2019-11-13 | Debiopharm Int Sa | Molecole leganti il cd37 e loro immunoconiugati |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20120107317A1 (en) * | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
| SG193447A1 (en) * | 2011-04-01 | 2013-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| WO2013088363A1 (en) * | 2011-12-13 | 2013-06-20 | Nordic Nanovector As | Chimeric therapeutic anti - cd37 antibodie hh1 |
| BR112014024487A2 (pt) * | 2012-03-30 | 2017-08-08 | Immunogen Inc | métodos para aumentar a eficácia da terapia baseada em cd37 |
| JP2015516980A (ja) * | 2012-04-26 | 2015-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とベンダムスチンとの併用 |
| WO2013171287A1 (en) * | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
| JP2015517512A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体の更なる薬剤との併用 |
| EP2852388A4 (en) * | 2012-05-23 | 2016-01-13 | Univ Johns Hopkins | COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| WO2014151438A1 (en) * | 2013-03-15 | 2014-09-25 | Emergent Product Development Seattle, Llc | Multispecific anti-cd37 antibodies and related compositions and methods |
| EP3008089A1 (en) * | 2013-06-14 | 2016-04-20 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with chlorambucil |
| US9925273B2 (en) | 2013-08-01 | 2018-03-27 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to CD37 proteins |
| US9291244B2 (en) | 2014-01-17 | 2016-03-22 | Ford Global Technologies, Llc | Nine speed automatic transmission |
| EP2966085A1 (en) | 2014-07-11 | 2016-01-13 | Boehringer Ingelheim International GmbH | Antibody IgG1 with a modified heavy chain constant region |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| CN108472361B (zh) | 2015-06-08 | 2022-12-27 | 德彪发姆国际有限公司 | 抗cd37免疫缀合物及抗cd20抗体组合物 |
| RS58167B1 (sr) * | 2015-07-28 | 2019-03-29 | Hoffmann La Roche | Unapređeni bakterijski endotoksinski test za određivanje endotoksina |
| CN108699144B (zh) | 2015-08-28 | 2022-07-19 | 德彪发姆国际有限公司 | 用于检测cd37的抗体和测定 |
| MX2018003292A (es) | 2015-09-21 | 2018-08-01 | Aptevo Res & Development Llc | Polipéptidos de unión a cd3. |
| CN109476756B (zh) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| US11013802B2 (en) * | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| CN118599009A (zh) | 2017-03-16 | 2024-09-06 | 综合医院公司 | 靶向cd37的嵌合抗原受体 |
| WO2018178396A1 (en) | 2017-03-31 | 2018-10-04 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| JP7278978B2 (ja) * | 2017-06-27 | 2023-05-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ａｓｇｒ１座位を含む非ヒト動物 |
| KR20210014684A (ko) | 2018-05-30 | 2021-02-09 | 데비오팜 인터네셔날 에스 에이 | 항-cd37 면역접합체 투약 용법 |
| EP3793578A4 (en) * | 2018-06-22 | 2022-03-23 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 and cd19 |
| MA52951A (fr) | 2018-06-22 | 2021-04-28 | Genmab Holding B V | Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci |
| JPWO2020004337A1 (ja) * | 2018-06-27 | 2021-08-02 | 国立大学法人東海国立大学機構 | Ｃｄ３７特異的キメラ抗原レセプター |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| MX2021003756A (es) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos. |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| CN114650867A (zh) * | 2019-08-30 | 2022-06-21 | 齐鲁普吉湾生物治疗公司 | 抗cd20抗体、抗cd37抗体及它们的混合物 |
| US12441816B2 (en) * | 2021-09-21 | 2025-10-14 | Qilu Puget Sound Biotherapeutics Corporation | Heterodimeric Fc for making fusion proteins and bispecific antibodies |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| EP4412715A1 (en) | 2021-10-06 | 2024-08-14 | Nordic Nanovector ASA | Humanized hh1 |
| TW202330041A (zh) * | 2021-10-18 | 2023-08-01 | 日商第一三共股份有限公司 | 抗cd37抗體-藥物結合物 |
| WO2024118480A1 (en) * | 2022-11-28 | 2024-06-06 | Epiphany Biosciences | Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses |
| WO2025083205A1 (en) | 2023-10-18 | 2025-04-24 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8800077D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel chimeric antibodies |
| EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| ES2146572T3 (es) * | 1988-09-06 | 2000-08-16 | Xoma Technology Ltd | Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano. |
| ATE289350T1 (de) | 1989-04-21 | 2005-03-15 | Amgen Inc | Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ES2193136T3 (es) | 1991-08-14 | 2003-11-01 | Genentech Inc | Variantes de inmunoglubina para receptores especificos de fc epsilon. |
| DK0563475T3 (da) | 1992-03-25 | 2000-09-18 | Immunogen Inc | Konjugater af cellebindende midler og derivater af CC-1065 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| WO1998005787A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| DE19911329A1 (de) | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| NZ517772A (en) | 1999-11-24 | 2004-03-26 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
| EP1242438B1 (en) | 1999-12-29 | 2006-11-08 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2004016753A2 (en) | 2002-08-15 | 2004-02-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP4703566B2 (ja) | 2003-05-14 | 2011-06-15 | イムノゲン インコーポレーティッド | 薬剤複合体組成物 |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| AU2006299429B2 (en) * | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| KR20150139636A (ko) | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| CA2691819A1 (en) | 2007-07-06 | 2009-02-19 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| US7919273B2 (en) | 2008-07-21 | 2011-04-05 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| EP2358390A1 (en) | 2008-11-13 | 2011-08-24 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic combination therapies and uses thereof |
| US20120189618A1 (en) * | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| JP2015516980A (ja) * | 2012-04-26 | 2015-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体とベンダムスチンとの併用 |
| WO2013171287A1 (en) * | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
| JP2015517512A (ja) * | 2012-05-16 | 2015-06-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３７抗体の更なる薬剤との併用 |
| EP3008089A1 (en) | 2013-06-14 | 2016-04-20 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with chlorambucil |
-
2008
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/en active Active
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 RS RS20150817A patent/RS54359B1/sr unknown
- 2008-08-08 EP EP10168244A patent/EP2241577A1/en not_active Withdrawn
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 CA CA2693464A patent/CA2693464C/en not_active Expired - Fee Related
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko not_active Expired - Fee Related
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/en active Active
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/en not_active Ceased
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
-
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
-
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
-
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
-
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
-
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
-
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812B1/en unknown
-
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
-
2016
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
-
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
-
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
-
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02300B (me) | Anti cd37 antitijela | |
| RU2742691C2 (ru) | Cd3-связывающий домен | |
| JP2022177090A5 (me) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| CN111484555B (zh) | 新型双特异性cd3/cd20多肽复合物 | |
| HRP20220637T1 (hr) | Protutijela anti-komplementa c1s i njihova upotreba | |
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| JP2017536829A5 (me) | ||
| JP2020515239A5 (me) | ||
| JP2018519263A5 (me) | ||
| FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon | |
| HRP20180243T1 (hr) | Dvostruko specifične vezivne molekule antigena za aktivaciju t stanica | |
| FI3177643T5 (fi) | T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| CA3130754A1 (en) | Multifunctional molecules that bind to t cell related cancer cells and uses thereof | |
| RU2013140433A (ru) | Человеческие антитела и конъюгаты антитело-препарат против cd74 | |
| JP2011509245A5 (me) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| HRP20240149T1 (hr) | Bispecifična molekula za vezanje antigena, koji vežu cd3 i cd20, i njihove upotrebe | |
| US20250277051A1 (en) | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| RU2012122203A (ru) | Композиции и способы для лечения восполительных нарушений | |
| RU2015108797A (ru) | Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки | |
| CN101831434B (zh) | 抗人cd45ra鼠免疫球蛋白可变区基因及用途 | |
| JPWO2022218380A5 (me) |